⌘ *Author's Choice*

Bet v 1 from Birch Pollen Is a Lipocalin-like Protein Acting as Allergen Only When Devoid of Iron by Promoting Th2 Lymphocytes[*]

Franziska Roth-Walter[‡], **Cristina Gomez-Casado**[§1], **Luis F. Pacios**[§], **Nadine Mothes-Luksch**[¶], **Georg A. Roth**[∥], **Josef Singer**[**2], **Araceli Diaz-Perales**[§], and **Erika Jensen-Jarolim**[‡**3]

*From the ‡Comparative Medicine Unit, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, and University of Vienna, A-1210 Vienna, Austria, the §Biotechnology Department, Center for Plant Biotechnology and Genomics, Technical University of Madrid, 28040 Madrid, Spain, ¶AllergyCare, 1220 Vienna, Austria, the ∥Department of Anesthesiology, General Intensive Care and Pain Medicine, Medical University of Vienna, Austria, and the **Unit of Comparative Immunology and Oncology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria*

Background: The reason of allergic sensitization to proteins like Bet v 1 is unknown.
Results: Bet v 1 binds iron via catechol-based siderophores. It can modulate human immune cells toward Th2 when not carrying iron.
Conclusion: Bet v 1 modulates immune cells toward Th2 when being devoid of iron.
Significance: We provide the functional basis under which circumstances Bet v 1 becomes an allergen.

It is hypothesized that allergens are at the borderline of self and non-self and, through as yet elusive circumstances, mount a Th2 response for allergic sensitization. The major birch pollen allergen Bet v 1 is considered the prototype for the PR-10 protein family causing respiratory allergy. Here, we give structural evidence that Bet v 1 is a lipocalin-like protein with a striking structural resemblance to human lipocalin 2. Lipocalin 2 is highly expressed in the lung where it exerts immunoregulatory functions dependent on being loaded with siderophore-bound iron (holo-form) or not (apo-form). We demonstrate that similar to lipocalin 2, Bet v 1 is capable of binding iron via catechol-based siderophores. Thereby, calculated K_d values of 66 nM surpassed affinities to known ligands nearly by a power of 10. Moreover, we give functional evidence of the immunomodulatory capacity of Bet v 1 being dependent on its iron-loaded state. When incubated to human immune cells, only the apo-form of Bet v 1, but not the holo-form, was able to promote Th2 cells secreting IL13. These results provide for the first time a functional understanding on the allergenicity of Bet v 1 and a basis for future allergen immunotherapies counteracting Th2 immune responses on a molecular basis.

One of the most studied allergens is Bet v 1, the major allergen of birch pollen. Even in classical analyses, it became apparent that among a plethora of proteins in crude birch pollen extract, only a single molecule harbors the IgE binding capacity (1, 2). The greatest majority of birch allergy patients (over >90%) react to Bet v 1, and as a consequence it is used as a marker for birch pollen allergy (3). Bet v 1 was cloned in 1989 and therefore in 2014 celebrates its 25th anniversary (4). To reveal the story behind the exclusive Th2 skewing capacity of Bet v 1, numerous studies subsequently analyzed and are still analyzing its T cell (5, 6) and B cell epitopes (6–8), the impact of its structure (9), or its specific uptake behavior by dendritic cells (10). Ever since structural analyses revealed the hydrophobic pocket within Bet v 1, a rush toward identification of putative ligand has gone on (11–14). Although several ligands have been proposed so far, none of these experiments have functionally explained the actual Th2 skewing capacity of Bet v 1.

Only a few protein families harbor the capacity to generate allergy. In contrast to the plant allergen Bet v 1 being the prototype of the PR-10 protein family (12), most animal-derived allergens belong to the lipocalin protein family (15). Interestingly, lipocalin 2 (LCN2)[4] is a human homologue to the animal lipocalins. LCN2 is specifically expressed at mucosal barriers where it exerts immunomodulatory functions (16–18) and does so at exactly the same site where respiratory allergens are encountered. Consequently, we hypothesized that a functional relationship might exist that could give some mechanistic insight into allergic sensitization.

4 The abbreviations used are: LCN2, lipocalin 2; FATCAT, Flexible structure AlignmenT by Chaining Aligned Fragment Pairs; CE, Combinatorial Extension; TM, Template Modeling; PBMC, peripheral blood mononuclear cell; PMA, phorbol 12-myristate 13-acetate.

FATCATflex   p-value= 0.0191
CE   z-score= 3.29
TM   TM-score= 0.413

c

Ligand	Affinity energy (kcal)	Dissociation constant Kd (nM)
Quercetin	-8.6	431
Quercetin-Fe	-9.3	130
Fe(catechol)3	-9.7	66

FIGURE 1. **Structural comparison of Bet v 1 with human LCN 2.** *a*, structural comparison of crystal structures of Bet v 1 (*blue*, 1BV1) and human LCN2 (*cyan*, 1L6M) proteins obtained with FATCATflex. *b*, Fe(catechol)$_3$ ligand (*sticks*) docked to Bet v 1 protein.

EXPERIMENTAL PROCEDURES

*Structural Analysis*We employed three different superposition procedures to compare the structure of allergens using (i) the FATCAT (Flexible structure AlignmenT by Chaining Aligned Fragment Pairs) (19), which allows flexibility in structurally aligned blocks by introducing a limited number of twists in the superposed structures; (ii) the CE (Combinatorial Extension) algorithm to align structural fragment pairs (20); and (iii) the TM (Template Modeling)-align procedure, which uses rotation matrices and dynamic programming to optimize a structure alignment (21). Both CE and TM methods yield superpositions referring to the protein structure as a whole, whereas FATCATflex superpositions may give two or more superposed structural blocks if one or more twists are introduced (as it is the case here for Bet v 1: Fig. 1).

For comparisons between crystal structures, FATCATflex and CE superpositions were accomplished by using the j-interface versions of these methods implemented in the PDB Comparison Tool (22). For FATCATflex comparisons involving model structures, the FATCAT server (23) and a version compiled for Linux of the CE program were used instead. TM-align superpositions were carried out in all cases using the TM website (21), which allows comparing experimental as well as theoretical structures. Superposed structures with FATCATflex *p* values < 0.05 are considered significantly similar, CE superpositions with *z*-scores between 3.0 and 4.0 suggest structural similarity, and TM-align superpositions with TM scores between 0.4 and 0.5 indicate significant structural relationship. Structural comparisons between NGAL (neutrophil gelatinase-associated lipocalin) wild-type protein and the allergen Bet v 1 were studied using the x-ray crystal structures (Protein Data Bank (PDB) code in parentheses) for NGAL (1L6M) and birch Bet v 1 (1BV1).

*Docking Analysis*AutoDock Vina (24) was used to dock the Fe(catechol)$_3$ ligand into the hydrophobic pocket of Bet v 1. The

TABLE 1
Affinity energy and dissociation constant of siderophores

Ligand	Affinity energy	Dissociation constant K_d
	kcal	*nM*
Quercetin	−8.6	431
Quercetin-iron	−9.3	130
Fe(catechol)$_3$	−9.7	66

protein was taken from the crystal structure of the Bet v 1-naringenin complex, PDB code 4A87 (13). The structure of the ligand was taken from our previous study on the binding of iron-catecholates to lipocalins (25). Docking input files for Bet v 1 and Fe(catechol)$_3$ were then generated with AutoDock Tools (26). A grid box of $20 \times 24 \times 28$ Å with origin at the center of the hydrophobic pocket of Bet v 1 was used in AutoDock Vina calculations. The docking geometry with lower affinity energy (−9.7 kcal/mol) was selected to model the Bet v 1-Fe(catechol)$_3$ complex (Table 1).

*Generation of Holo-Bet v 1*Recombinant Bet v 1a was incubated with an equimolar concentration of iron (ammonium iron (III) citrate, Sigma) and a 3-fold molar concentration of catechol because three catechols are necessary for hexadental binding of iron in the LCN2 pocket against deionized water.

*Isolation of PBMCs*The study was approved by the Institutional Ethics Committee of the Medical University of Vienna and conducted in accordance with the Helsinki Declaration of 1975. Ten volunteers donated 15 ml of blood. All subjects gave their full written informed consent.

Blood was mixed with equal volumes of PBS containing 2% FCS before applying onto 10 ml of Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) followed by centrifugation at $400 \times g$ for 30 min without break and washing the cells twice with 0.89% sodium chloride solution. Cells were then diluted to a concentration of 1×10^6 cells/ml in RPMI medium containing 10% FCS. Throughout the study FCS from the same lot was used.

*Stimulation of PBMCs*To peripheral blood mononuclear cells (PBMCs) (0.5 Mio/test), a final concentration of 0.75 ng/ml phorbol 12-myristate 13-acetate (PMA), 100 μg/ml apo-Bet v 1 in the presence or absence of 30 μM catechol (Sigma) and 10 μM iron was added. Controls included PMA alone or in the presence of 30 μM catechol (Sigma) and 10 μM iron. PMA concentration was determined in pre-experiments and considered optimal when cells were slightly down-regulating surface CD4$^+$ expression (27). After 18 h supernatants were collected and stored at −80 °C until further analysis.

Cells were stained for 30 min at 4 °C with CD3-APC (clone SK7, eBioscience (Santa Clara, CA)), CD4-PE-Cy7 (clone SK3, BD Biosciences), and CD8-PE (clone SK1, BD Biosciences), in PBS containing 2% FCS followed by a 10-min incubation of annexin V FITC (BD Bioscience) and 7-amino-actinomycin D (eBioscience) in binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl$_2$) at room temperature. Acquisition and analysis were performed on a FACSCanto II machine (BD Biosciences) using the FACSDiva Software 6.0.

*Determination of Cytokines*IL13 and IFNγ were detected with commercially available kits according to the manufacturers' protocol using undiluted supernatants. ELISAs for human

FIGURE 2. **Apo-, but not holo-Bet v 1 promotes Th2 cells.** PBMCs were treated with PMA alone or in the presence of apo- or holo-Bet v 1. *a*, representative pictograms of CD3 gated PBMCs plotted for CD4 and CD8. *b*, percentage of $CD3^+CD4^+$ cells. *c*, percentage of $CD3^+CD8^+$ cells. Statistical analyses were conducted with repeated measures analysis of variance following Newman-Keuls multiple comparison test. ***, $p < 0.001$, *ns*, not significant.

IL13 and IFNγ were from eBioscience, both assays having a reported sensitivity of 4 pg/ml.

Statistical Analysis—Statistical analyses were conducted with repeated measures analysis of variance following Newman-Keuls multiple comparison test using GraphPad Prism 5 software (GraphPad, San Diego, CA). $p < 0.05$ was considered statistically significant.

RESULTS

Bet v 1 Resembles Human Lipocalin 2—In our first approach, we compared the structure of the major birch pollen allergen Bet v 1 with human LCN2 using three different superposition procedures (FATCATflex, CE, and TM). Superimposition of Bet v 1 (1BV1) with LCN2 (1L6M) revealed a very similar core structure around the hydrophobic pocket (*p* value 0.0126, score 126.12, root mean square deviation 3.15). Further analysis with CE superpositions resulted in a *z*-score of 3.29, suggesting structural similarity, and TM-align superpositions calculated a TM score of 0.413, indicating significant structural relationship.

Affinity of Bet v 1 to Iron-Siderophore Complexes—For docking experiments, the crystal structure of the Bet v 1-naringenin complex was taken from PDB code 4A87 (13), and the structure of the ligand was taken from our previous study on the binding of iron-catecholates to lipocalins (25). Docking analyses with

the previously reported natural ligand quercetin resulted in affinity energy of −8.6 kcal/mol and a dissociation constant, K_d, of 431 nM. The virtual addition of Fe(III) to the quercetin ligand improved affinity energy to −9.3 kcal/mol and lowered K_d to 130 nM. Binding of iron-catecholates to Bet v 1 resulted in −9.6 kcal/mol affinity energy and a K_d of 66 nM. Hence, the addition of iron improved affinity energy greatly, suggesting that Bet v 1 might function as an iron carrier protein.

Apo- but Not Holo-Bet v 1 Promotes Th2 Cells—LCN2 is able to drive immune responses dependent on its iron-loading state. Consequently, we next tested whether the holo- or apo-birch pollen allergen Bet v 1 was also able to skew the immune system toward Th2, thereby enabling isotype switch and the generation of IgE antibodies (18, 19). We activated PBMCs from healthy and allergic individuals with a low concentration of PMA, and apo- or holo-Bet v 1 for 18 h *in vitro*, and analyzed CD3 cells for their CD4 and CD8 expression. Further, we checked the secretion of typical Th1 (IFNγ) and Th2 (IL13) cytokines. Indeed, Bet v 1 stimulation was associated with an increased percentage of $CD3^+CD4^+$ lymphocytes (Fig. 2, *a* and *b*), but only when the apo-form was introduced. $CD8^+$ numbers were not affected when applying lipocalin allergens in either the apo-form or the holo-form to immune cells (Fig. 2, *a* and *c*). The

FIGURE 3. **Apo-, but not holo-lipocalin allergen promotes secretion of IL13.** *a* and *b*, IL13 levels (*a*) and IFNγ levels (*b*) of stimulated PBMCs. Statistical analyses were conducted with repeated measures analysis of variance following Newman-Keuls multiple comparison test. **, $p < 0.01$, *ns*, not significant.


FIGURE 4. **Annexin V staining of CD4 cells.** PBMCs were treated with PMA alone or in the presence of apo- or holo-Bet v 1. *a*, representative pictograms of PBMCs plotted for CD4 and annexin V (*AnnV*). *b*, percentage of CD4 cells. *c*, percentage of annexin V-positive CD4 cells. Statistical analyses were conducted with repeated measures analysis of variance following Newman-Keuls multiple comparison test. ***, $p < 0.001$, *, $p < 0.05$, *ns*, not significant.

promoted CD4$^+$ cells could indeed be classified as Th2-cells because IL13 could already be detected after 18 h in their supernatants (Fig. 3). No differences in IFNγ secretion between apo- or holo-Bet v 1 were observed (Fig. 3). In contrast, holo-Bet v 1 significantly reduced the numbers of CD3$^+$CD4$^+$ cells, but not of CD8$^+$ cells. Additionally, no IL13 was produced (Figs. 2 and 3). CD4$^+$ cell expression was noticeably up-regulated upon the addition of apo-Bet v 1, whereas the addition of holo-Bet v 1 drastically reduced CD4$^+$ expression. A significantly higher percentage of CD4$^+$ cells were positive for annexin V when cells were incubated with holo-Bet v 1, which was not observed when cells were incubated with apo-Betv1. Hence, relatively more CD4 cells underwent apoptosis when human immune cells were exposed to holo-Bet v 1 (Fig. 4). Thus, Bet v 1 was able to mount a Th2 response in its apo-form, but it abrogated an immune response partly by induction of apoptosis when introduced to immune cells in its holo-form.

DISCUSSION

The mechanisms of sensitization are poorly understood, and most data have focused on allergic reactions of the respiratory tract rather than on the initial steps of allergic sensitization. We hypothesized that the nature of allergens *per se* contributes to the priming process and that priming occurs when allergens interfere with our own immune system.

Only a very limited number of protein families are truly able to cause allergic sensitization. Allergens predominantly causing respiratory allergies usually belong to the lipocalin protein family comprising nearly all major animal-derived allergens (15), and plant major allergens usually originate from the prolamin or cupin superfamilies, as well as the family so far being classified as PR-10 (12).

One interesting aspect of these proteins, which is usually not addressed, is that despite their high allergenic potential, they usually have a very low immunogenicity (28). They seem to suppress the immune system rather than to activate it. Consid-

ering that most people tolerate them fairly well, this should be the normal situation. However, under certain circumstances, this normal immune response is skewed.

To our surprise, the major birch pollen allergen Bet v 1 had a striking structural resemblance to human LCN2 when we compared it with human LCN2. The resemblance of Bet v 1 to LCN2 is remarkable considering its distant phylogenetic relation and prompted us to the hypothesis that the biological function of Bet v 1 might be similar to LCN2 as well.

Recently, the natural ligand of Bet v 1 was identified as being quercetin (11), which is a catechol derivate known for its ability to bind iron (29). Consequently, we next calculated *in silico* the affinity of Bet v 1 to quercetin alone, in conjunction with iron, or to Fe(catechol)$_3$ by docking analysis (24). Confirming our hypothesis, affinity was increased 3-fold when iron was added to the natural ligand quercetin, and binding affinity of iron complexed with three catechols, Fe(catechol)$_3$, even reached a K_d value of 66 nM. The binding to iron-siderophore thereby was calculated as being nearly 10-fold stronger than with any other ligand described so far.

Our data using Bet v 1 as a model allergen clearly demonstrate that the ligand is decisive in modulating the immunosuppressive environment toward Th2. We provide here for the first time data suggesting Bet v 1 as a carrier for iron-siderophore complexes.

Moreover, we give evidence that the mode of action by which Bet v 1 is able to skew the immune system toward Th2 is similar to that seen by the immunoregulatory protein lipocalin 2, the function of which depends on its iron-loaded state. We show that Bet v 1 *per se* was able to mount a Th2 response when the allergen was introduced to the immune cells in the apo-form, and we give evidence that applying the protein in its holo-form can inhibit the Th2-skewing potential of Bet v 1.

In this study, we focus our attention on the initial steps of allergic sensitization. Here, we definitely could demonstrate that the apo-form of Bet v 1 is able to prime T cells toward Th2. We did not yet address whether the induced T cells are also important in the effector phase, when re-exposure to the allergen occurs. We anticipate that because allergic individuals, once sensitized, remain allergic to birch, the holo-form of Bet v 1 is also capable of eliciting allergic reactions.

We believe that the obtained results have significant implications not only for the understanding of the origin of an allergen-induced Th2 response, but likely for improvement of allergen immunotherapy as well. In light of this knowledge, we consider Bet v 1 to be a lipocalin allergen, contributing thereby further to a shrinking of the list of protein families known to cause sensitization.

Hence, we postulate that under steady-state conditions, allergens are immunosuppressive when presented in the holo-form to the immune system. We hypothesize that under certain conditions such as inflammation or infections, in which immune cells are iron-deprived, allergens lose their iron-siderophore complexes and are presented to the immune system in their apo-form, leading to a Th2 skewing.

The efficacy of allergen immunotherapy up to now (30) has varied dependent on the allergen extracts used, in particular because the exact mechanisms of desensitization are a complex interplay of immunosuppressive factors. The intrinsic potential of natural Bet v 1 to trigger IgE-mediated responses, undesired during allergen immunotherapy, has been understood and circumvented by the construction of many hypoallergenic variants of Bet v 1, which have entered clinical trials (31). Allergen immunotherapy is still a long-lasting treatment, finally leading to the desired Th1 shift (32). In light of the current findings, we are prompted to state that in the future, spiking of apo-Bet v 1 with iron will be a simpler approach and will likely improve the efficacy of allergen immunotherapy against birch pollen.

REFERENCES

1. Ipsen, H., Wihl, J. A., Petersen, B. N., and Løwenstein, H. (1992) Specificity mapping of patients IgE response towards the tree pollen major allergens Aln g I, Bet v I and Cor a I. *Clin. Exp. Allergy* **22,** 391–399
2. Jarolim, E., Rumpold, H., Endler, A. T., Schlerka, G., Ebner, H., Scheiner, O., and Kraft, D. (1989) Specificities of IgE and IgG antibodies in patients with birch pollen allergy. *Int. Arch. Allergy Appl. Immunol.* **88,** 180–182
3. Sekerková, A., and Poláková, M. (2011) Detection of Bet v1, Bet v2 and Bet v4 specific IgE antibodies in the sera of children and adult patients allergic to birch pollen: evaluation of different IgE reactivity profiles depending on age and local sensitization. *Int. Arch. Allergy Immunol.* **154,** 278–285
4. Breiteneder, H., Pettenburger, K., Bito, A., Valenta, R., Kraft, D., Rumpold, H., Scheiner, O., and Breitenbach, M. (1989) The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. *EMBO J.* **8,** 1935–1938
5. Ebner, C., Schenk, S., Najafian, N., Siemann, U., Steiner, R., Fischer, G. W., Hoffmann, K., Szépfalusi, Z., Scheiner, O., and Kraft, D. (1995) Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. *J. Immunol.* **154,** 1932–1940
6. Mutschlechner, S., Egger, M., Briza, P., Wallner, M., Lackner, P., Karle, A., Vogt, A. B., Fischer, G. F., Bohle, B., and Ferreira, F. (2010) Naturally processed T cell-activating peptides of the major birch pollen allergen. *J. Allergy Clin. Immunol.* **125,** 711–718, 718.e1–718.e2
7. Schöll, I., Kalkura, N., Shedziankova, Y., Bergmann, A., Verdino, P., Knittelfelder, R., Kopp, T., Hantusch, B., Betzel, C., Dierks, K., Scheiner, O., Boltz-Nitulescu, G., Keller, W., and Jensen-Jarolim, E. (2005) Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. *J. Immunol.* **175,** 6645–6650
8. Ganglberger, E., Grunberger, K., Sponer, B., Radauer, C., Breiteneder, H., Boltz-Nitulescu, G., Scheiner, O., and Jensen-Jarolim, E. (2000) Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE. *FASEB J.* **14,** 2177–2184
9. Gajhede, M., Osmark, P., Poulsen, F. M., Ipsen, H., Larsen, J. N., Joost van Neerven, R. J., Schou, C., Løwenstein, H., and Spangfort, M. D. (1996) X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. *Nat. Struct. Biol.* **3,** 1040–1045
10. Smole, U., Balazs, N., Hoffmann-Sommergruber, K., Radauer, C., Hafner, C., Wallner, M., Ferreira, F., Grössinger, R., de Jong, E. C., Wagner, S., and Breiteneder, H. (2010) Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001. *Immunobiology* **215,** 903–909
11. Seutter von Loetzen, C., Hoffmann, T., Hartl, M. J., Schweimer, K., Schwab, W., Rösch, P., and Hartl-Spiegelhauer, O. (2014) Secret of the major birch pollen allergen Bet v 1: identification of the physiological ligand. *Biochem. J.* **457,** 379–390
12. Radauer, C., Lackner, P., and Breiteneder, H. (2008) The Bet v 1 fold: an ancient, versatile scaffold for binding of large, hydrophobic ligands. *BMC Evol. Biol.* **8,** 286
13. Kofler, S., Asam, C., Eckhard, U., Wallner, M., Ferreira, F., and Brandstet-

ter, H. (2012) Crystallographically mapped ligand binding differs in high and low IgE binding isoforms of birch pollen allergen bet v 1. *J. Mol. Biol.* **422,** 109 –123

14. Mogensen, J. E., Wimmer, R., Larsen, J. N., Spangfort, M. D., and Otzen, D. E. (2002) The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands. *J. Biol. Chem.* **277,** 23684 –23692

15. Virtanen, T. (2001) Lipocalin allergens. *Allergy* **56,** Suppl 67, 48 –51

16. Devireddy, L. R., Gazin, C., Zhu, X., and Green, M. R. (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. *Cell* **123,** 1293–1305

17. Devireddy, L. R., Teodoro, J. G., Richard, F. A., and Green, M. R. (2001) Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. *Science* **293,** 829 – 834

18. Kehrer, J. P. (2010) Lipocalin-2: pro- or anti-apoptotic? *Cell Biol. Toxicol.* **26,** 83– 89

19. Ye, Y., and Godzik, A. (2003) Flexible structure alignment by chaining aligned fragment pairs allowing twists. *Bioinformatics* **19,** Suppl. 2, ii246 –ii255

20. Shindyalov, I. N., and Bourne, P. E. (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. *Protein Eng.* **11,** 739 –747

21. Zhang, Y., and Skolnick, J. (2005) TM-align: a protein structure alignment algorithm based on the TM-score. *Nucleic Acids Res.* **33,** 2302–2309

22. Prlic, A., Bliven, S., Rose, P. W., Bluhm, W. F., Bizon, C., Godzik, A., and Bourne, P. E. (2010) Pre-calculated protein structure alignments at the RCSB PDB website. *Bioinformatics* **26,** 2983–2985

23. Ye, Y., and Godzik, A. (2004) FATCAT: a web server for flexible structure comparison and structure similarity searching. *Nucleic Acids Res.* **32,** W582–W585

24. Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **31,** 455– 461

25. Gómez-Casado, C., Roth-Walter, F., Jensen-Jarolim, E., Díaz-Perales, A., and Pacios, L. F. (2013) Modeling iron-catecholates binding to NGAL protein. *J. Mol. Graph. Model.* **45,** 111–121

26. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., and Olson, A. J. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **30,** 2785–2791

27. Kaldjian, E., McCarthy, S. A., Sharrow, S. O., Littman, D. R., Klausner, R. D., and Singer, A. (1988) Nonequivalent effects of PKC activation by PMA on murine CD4 and CD8 cell-surface expression. *FASEB J.* **2,** 2801–2806

28. Roth-Walter, F., Berin, M. C., Arnaboldi, P., Escalante, C. R., Dahan, S., Rauch, J., Jensen-Jarolim, E., and Mayer, L. (2008) Pasteurization of milk proteins promotes allergic sensitization by enhancing uptake through Peyer's patches. *Allergy* **63,** 882– 890

29. Cho, E. A., Song, H. K., Lee, S. H., Chung, B. H., Lim, H. M., and Lee, M. K. (2013) Differential in vitro and cellular effects of iron chelators for hypoxia inducible factor hydroxylases. *J. Cell. Biochem.* **114,** 864 – 873

30. Akdis, M., and Akdis, C. A. (2014) Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. *J. Allergy Clin. Immunol.* **133,** 621– 631

31. Purohit, A., Niederberger, V., Kronqvist, M., Horak, F., Grönneberg, R., Suck, R., Weber, B., Fiebig, H., van Hage, M., Pauli, G., Valenta, R., and Cromwell, O. (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. *Clin. Exp. Allergy* **38,** 1514 –1525

32. Möbs, C., Ipsen, H., Mayer, L., Slotosch, C., Petersen, A., Würtzen, P. A., Hertl, M., and Pfützner, W. (2012) Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. *J. Allergy Clin. Immunol.* **130,** 1108 –1116